Barclays
AVIR icon

Barclays’s Atea Pharmaceuticals AVIR Stock Holding History

Barclays’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.62M Buy
348,653
+187,707
+117% +$934K ﹤0.01% 2472
2026
Q1 		$866K Sell
160,946
-82,044
-34% -$377K ﹤0.01% 2839
2025
Q4 		$867K Buy
242,990
+1,526
+0.6% +$4.85K ﹤0.01% 3539
2025
Q3 		$700K Sell
241,464
-20,310
-8% -$69.4K ﹤0.01% 3594
2025
Q2 		$942K Buy
261,774
+90,462
+53% +$270K ﹤0.01% 3379
2025
Q1 		$512K Sell
171,312
-28,801
-14% -$89.9K ﹤0.01% 3519
2024
Q4 		$670K Buy
200,113
+23,036
+13% +$76.6K ﹤0.01% 3647
2024
Q3 		$593K Buy
177,077
+75,624
+75% +$274K ﹤0.01% 3671
2024
Q2 		$336K Sell
101,453
-44,079
-30% -$164K ﹤0.01% 3276
2024
Q1 		$588K Sell
145,532
-51,555
-26% -$202K ﹤0.01% 3489
2023
Q4 		$601K Buy
197,087
+171,468
+669% +$519K ﹤0.01% 3769
2023
Q3 		$76.9K Buy
25,619
+10,348
+68% +$35.2K ﹤0.01% 3686
2023
Q2 		$57.1K Sell
15,271
-23,488
-61% -$87.9K ﹤0.01% 3775
2023
Q1 		$130K Buy
38,759
+12,677
+49% +$51.4K ﹤0.01% 4042
2022
Q4 		$125K Sell
26,082
-10,941
-30% -$55.3K ﹤0.01% 4100
2022
Q3 		$211K Sell
37,023
-9,917
-21% -$75.9K ﹤0.01% 3166
2022
Q2 		$333K Sell
46,940
-15,070
-24% -$103K ﹤0.01% 3125
2022
Q1 		$448K Buy
+62,010
New +$421K ﹤0.01% 2975

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Barclays's AVIR Position: Q2 2026 in Review

Barclays increased its Atea Pharmaceuticals (AVIR) stake by 117% in Q2 2026, buying an estimated $934K and bringing the position to 348,653 shares worth $1.62M. The position accounts for ﹤0.01% of the portfolio, ranked #2472.

Barclays first reported a position in AVIR in Q1 2022 and has held it in 18 quarters since. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Barclays held 348,653 shares of Atea Pharmaceuticals worth $1.62M as of Q2 2026.
  • Barclays bought 187,707 Atea Pharmaceuticals shares in Q2 2026, an estimated $934K.
  • Atea Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2472 holding.
  • Barclays first reported a position in Atea Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.